Lilly issues licenses to Dr Reddyâs, MSN, Torrent Pharma for commercialisation of baricitinib
Lilly issues licenses to Dr Reddyâs, MSN, Torrent Pharma for commercialisation of baricitinib
13 May 2021 | News Dr Reddyâs Ltd, MSN Laboratories and Torrent Pharmaceuticals will be collaborating with Lilly to accelerate and expand the availability of baricitinib in India
Source credit: Shutterstock
Eli Lilly and Company announced that it has issued additional royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Dr Reddy’s Ltd, MSN Laboratories and Torrent Pharmaceuticals, who will be collaborating with Lilly to accelerate and expand the availability of baricitinib in India. These three additional voluntary licensing agreements will ensure high quality manufacturing and accessibility of baricitinib during this pandemic improving the local treatment options available to positively impact the liv
Sun Pharma share hits new 52-week high after firm wins licence to make Covid-19 drug
The three Indian drugmakers - Cipla Ltd, Lupin Ltd, and Sun Pharma will collaborate with Lilly to manufacture and distribute Baricitinib in India. The drug is approved by the Central Drugs Standard Control Organization (CDSCO) for restricted emergency use in India
BusinessToday.In | May 11, 2021 | Updated 12:47 IST
Representative Image
Shares of Sun Pharma Industries rose over 3 per cent to hit a new 52-week high of Rs 721.90 in the morning session after the pharma major announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with US-based Eli Lilly for expanding access to Lilly s drug, Baricitinib in India.
Sun Pharma share hits new 52-week high after firm wins licence to make Covid-19 drug
The three Indian drugmakers - Cipla Ltd, Lupin Ltd, and Sun Pharma will collaborate with Lilly to manufacture and distribute Baricitinib in India. The drug is approved by the Central Drugs Standard Control Organization (CDSCO) for restricted emergency use in India
BusinessToday.In | May 11, 2021 | Updated 12:47 IST
Representative Image
Shares of Sun Pharma Industries rose over 3 per cent to hit a new 52-week high of Rs 721.90 in the morning session after the pharma major announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with US-based Eli Lilly for expanding access to Lilly s drug, Baricitinib in India.
Lupin in order to expand access. Baricitinib, in combination with remdesivir, received emergency approval last year from the USFDA for treatment of hospitalised Covid-19 patients who are not on ventilator support.
Baricitinib is normally used to treat arthiritis.
As the threat of compulsory licence (CL) looms over big pharma in India, companies are rushing in to sign voluntary licensing agreements that might potentially help them stave off demands for compulsory licence from activists, and questions from courts.
Hyderabad-based Natco Pharma and a couple of health activist groups have filed petitions in the Supreme Court asking the apex court to direct the Indian government to issue CL under Section 92 of the Indian Patent Act that allows this in order to expand manufacturing of a critical drug during a national emergency.